Eli Lilly (LLY)
(Delayed Data from NYSE)
$797.45 USD
+21.07 (2.71%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $798.95 +1.50 (0.19%) 7:04 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$797.45 USD
+21.07 (2.71%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $798.95 +1.50 (0.19%) 7:04 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
by Zacks Equity Research
The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
by Zacks Equity Research
Nektar (NKTR) reports a wider-than-expected loss in the fourth quarter of 2023 while revenue beat estimates.
Eli Lilly (LLY) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $792.28, marking a +1.3% move from the previous day.
The Zacks Analyst Blog Highlights Eli Lilly, The Procter & Gamble, Morgan Stanley, AT&T and Medtronic
by Zacks Equity Research
Eli Lilly, The Procter & Gamble, Morgan Stanley, AT&T and Medtronic are part of the Zacks top Analyst Blog.
Top Analyst Reports for Eli Lilly, Procter & Gamble & Morgan Stanley
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), The Procter & Gamble Company (PG) and Morgan Stanley (MS).
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
by Zacks Equity Research
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks Market Edge Highlights: AAPL, COST, WSM, LLY and HLT
by Zacks Equity Research
AAPL, COST, WSM, LLY and HLT have been highlighted in this Market Edge article.
How to Start Stock Investing in Your 50s
by Tracey Ryniec
Think you're too old to start buying stocks? Think again. Here's some tips.
5 Best-Performing S&P 500 Stocks Halfway Through Q1
by Sweta Killa
Nvidia (NVDA), Eli Lilly (LLY), Meta Platforms (META), Uber Technologies (UBER) and Ralph Lauren (RL) are the five best-performing stocks in the S&P 500.
The Zacks Analyst Blog Highlights Mastercard, SAP, CrowdStrike, Eli Lilly and AMETEK
by Zacks Equity Research
Mastercard, SAP, CrowdStrike, Eli Lilly and AMETEK are part of the Zacks top Analyst Blog.
Top Stock Reports for Mastercard, SAP & CrowdStrike
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), SAP SE (SAP) and CrowdStrike Holdings, Inc. (CRWD).
Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Incyte's (INCY) fourth-quarter 2023 earnings and revenues miss estimates. Quarterly revenues cross the $1 billion mark for the first time on the continued growth of Jakafi and the strong launch of Opzelura.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
A Look at Pharma ETFs After Q4 Earnings
by Sweta Killa
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Pharma Stock Roundup: AZN & LLY's Q4 Earnings, NVO, NVS & MRK's M&A Deals
by Kinjel Shah
Eli Lilly (LLY) and AstraZeneca (AZN) announce fourth-quarter results. Novo Nordisk (NVO), Merck (MRK) and Novartis (NVS) make M&A announcements.
Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development
by Zacks Equity Research
Foghorn (FHTX) gains 55% as its strategic collaboration partner, Lilly, selects the pre-clinical candidate, FHD-909, for clinical development.
Zacks Market Edge Highlights: NVDA, LLY, CMG, DECK and VRT
by Zacks Equity Research
NVDA, LLY, CMG, DECK and VRT have been highlighted in this Market Edge article.
Should You Buy a Stock on its All-Time Highs?
by Tracey Ryniec
There is a stock you love but it's red hot and has gone vertical. Do you dive in or wait for a sell-off?
ETFs to Buy as Mounjaro Powers Eli Lilly's Q4 Earnings Beat
by Sweta Killa
Eli Lilly and Company (LLY) posted robust fourth-quarter 2023 earnings, beating estimates on both the top and bottom lines driven by strong sales of its diabetes and weight-loss treatments.
Amgen (AMGN) Q4 Earnings Top, Horizon Drugs Drive Sales
by Zacks Equity Research
Amgen (AMGN) beats fourth-quarter estimates for earnings and sales. Horizon's products add $954 million in sales in the quarter.
Compared to Estimates, Lilly (LLY) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge.
Eli Lilly (LLY) Q4 Earnings Beat, Mounjaro, Zepbound Drive Sales
by Zacks Equity Research
Eli Lilly (LLY) beats fourth-quarter estimates for earnings as well as sales. The company issues an upbeat guidance for 2024.